press release Heajin Kim 3/9/25 press release Heajin Kim 3/9/25 Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference Read More press release Heajin Kim 3/6/25 press release Heajin Kim 3/6/25 Luxa's stem cell therapy for dry AMD shows early promise Read More Latest Notice Heajin Kim 2/19/25 Latest Notice Heajin Kim 2/19/25 Luxa’s Expanded Access Policy Read More press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More Heajin Kim 10/1/24 Heajin Kim 10/1/24 Read More Older Posts
press release Heajin Kim 3/9/25 press release Heajin Kim 3/9/25 Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference Read More
press release Heajin Kim 3/6/25 press release Heajin Kim 3/6/25 Luxa's stem cell therapy for dry AMD shows early promise Read More
Latest Notice Heajin Kim 2/19/25 Latest Notice Heajin Kim 2/19/25 Luxa’s Expanded Access Policy Read More
press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More
